The majority of current studies regarding the use of methadone (MTD) in the treatment of
cancer pain are focused in its administration via the oral route (PO). The ratio considered
from VO to parenteral route (BP) is 2:1. Academic literature assumes the ratio from BP to VO
to be 1:2. In our unit, we use MTD in the context of ROP and not as the last opioid. If face
with a situation where there is a good control of pain with MTD BP, usually we move to VO. We
have observed that the traditional ratio tend to produce certain toxicity problems. Because
of this, we have proposed a new ratio of conversion from PAR MTD to oral MTD, i.e. 1:1.2
Phase:
Phase 3
Details
Lead Sponsor:
L'Hospitalet de Llobregat
Collaborators:
Hospital Arnau de Vilanova Hospital Universitario La Paz